Hogan Thomas E. sold $1.6M of CLBT

Hogan Thomas E. (Chief Executive Officer) sold 103,188 shares of Cellebrite DI Ltd. (CLBT) at $15.76 ($1.63M total) on 2026-07-02.

Original reporting
SEC EDGAR · Hogan Thomas E.
Published Jul 7, 2026, 11:29 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 7, 2026, 11:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLBT
Neutral
high confidence
Mentioned
$CLBT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity, but the text contains no new guidance, contracts, litigation, or operational developments.

02

Market read

A $1.63M CEO open-market sale is disclosed; likely sentiment-only unless corroborated by other new catalysts.

03

What to watch

No 10b5-1 plan is stated, but the article also provides no reason for the sale or any concurrent buying/selling pattern beyond this single transaction.

Relevance 6/10Novelty 5/10Timing: Filed July 7; reflects sale executed July 2.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Cellebrite DI Ltd. (CLBT).

Company-level read

Ticker impact

$CLBTNeutralHigh confidence
Context

Cellebrite CEO Hogan Thomas E. sold 103,188 shares in an open-market transaction worth about $1.63M, per Form 4 filed July 7.

Expected impact

Low near-term impact; any reaction is likely limited unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider sale with no 10b5-1 plan and no accompanying operational/regulatory update in the text.

Market effects

Minimal—this is an issuer-specific insider transaction with no sector-wide signal provided.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or liquidity needs; without additional context, it may not indicate deteriorating fundamentals.

Key entities

  • Cellebrite DI Ltd.

    Public company subject of the Form 4 insider sale disclosure.

  • Hogan Thomas E.

    CEO and officer/director who sold shares via open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLBTHighAI 8/10

Cellebrite DI Ltd. (CLBT): Financial results for Q3 2026

Cellebrite DI Ltd. (CLBT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Cellebrite Reports Third-Quarter 2026 Results Third-Quarter ARR Growth of 20% and TTM Free Cash Flow Margin of 31% Net income of $26.7 million; Non-GAAP net income of $45.6 million and adjusted EBITDA of $53.6 million, 36% adjusted EBITDA margin TYSONS CORNER, VA and

$CLBTHigh

Cellebrite Reports Third-Quarter 2026 Results

Cellebrite reported Q3 2026 results with ARR up 20% to $528.5M, revenue up 18% to $149M, and adjusted EBITDA of $53.6M. CEO Shiv Ramji highlighted strong international and U.S. Federal performance, and raised 2026 adjusted EBITDA outlook to $163M-$166M. The company also announced plans to redomicile in the U.S. and progress with its Genesis AI solution.

$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.